Clinical trial · Interventional
Neuroplasticity-Based Cognitive Remediation for Chemotherapy-Related Cognitive Impairment
NCT04230863CI-TRIAL-00054285completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The investigators propose to apply neuroplasticity-based computerized cognitive remediation (nCCR) to treat chemotherapy-related cognitive impairment (CRCI).
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer Survivors | — | UNRESOLVED | — |
| Chemotherapy-related Cognitive Impairment | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Neuroplasticity-based Computerized Cognitive Remediation | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Neuroplasticity-based Computerized Cognitive Remediation
- description
- Participants will receive a 45-hour of Neuroplasticity-based Computerized Cognitive Remediation.
- interventionNames
- Behavioral: Neuroplasticity-based Computerized Cognitive Remediation
Primary outcomes (3)
- measure
- Evaluate completion rates of nCCR
- timeFrame
- 2 years
- description
- Assess the percentage of enrolled participants who completed of the 40-hour nCCR treatment
- measure
- Evaluate visit frequency throughout nCCR treatment
- timeFrame
- through study completion, an average of 5 weeks.
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 35 Years
- Maximum age
- 80 Years
Show eligibility criteria text
1. Inclusion Criteria: All participants will: 1. Be between 35 and 80 years of age, 2. Have been diagnosed with noninvasive or invasive (Stage 1, 2, or 3A) breast cancer, colon cancer, lymphoma, endometrial cancer or ovarian cancer 3. Have undergone treatment with systemic chemotherapy within the last 1-8 years, 4. Endorse persistent CRCI subjective complaints (as defined below), 5. Have no active cardiac, neurologic, or psychiatric illness, 6. Fluent in and able to read English. 2. Exclusion Criteria: Participants will be excluded for: 1. Any active neurologic psychiatric disease, clinically significant cognitive impairment or dementia, history of significant head trauma followed by persistent neurologic deficits, or known structural brain abnormalities, 2. Current major depression or another major psychiatric disorder as described in DSM-5 (use of CNS active medications (e.g. antidepressants) will be permitted, provided dosing has been stable for at least 3 months), 3. Any history of alcohol or substance abuse or dependence within the past 2 years (DSM-5 criteria), 4. Any significant systemic illness or unstable medical condition which could lead to difficulty complying with the protocol. 5. Use of any investigational drugs within 30 days or 5 half-lives, whichever is longer, prior to screening, and 6. Use of cholinergic agents will be discouraged but will be reviewed on a case-by-case basis by the PI. 7. Red-green color blindness. Other types of color blindness will be reviewed on a case-by-case basis by the PI.
References
Publications (0)
Data not yet available
No reference posted for this study.